<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:52:39 -0700</creation_date>
  <update_date>2013-05-27 11:23:45 -0600</update_date>
  <accession>HMDBP00972</accession>
  <secondary_accessions>
    <accession>6260</accession>
    <accession>HMDBP07113</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>5-LO</synonym>
    <synonym>5-lipoxygenase</synonym>
  </synonyms>
  <gene_name>ALOX5</gene_name>
  <general_function>Involved in metal ion binding</general_function>
  <specific_function>Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
</specific_function>
  <pathways>
    <pathway>
      <name>leukotriene A4 biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Arachidonic acid metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00590</kegg_map_id>
    </pathway>
    <pathway>
      <name>Serotonergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04726</kegg_map_id>
    </pathway>
    <pathway>
      <name>Toxoplasmosis</name>
      <smpdb_id/>
      <kegg_map_id>map05145</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB11135</accession>
      <name>5-HPETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06940</accession>
      <name>9(S)-HPODE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00692</accession>
      <name>Fe2+</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00673</accession>
      <name>Linoleic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01043</accession>
      <name>Arachidonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01193</accession>
      <name>5(S)-Hydroperoxyeicosatetraenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01337</accession>
      <name>Leukotriene A4</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01964</accession>
      <name>Caffeic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01893</accession>
      <name>Alpha-Tocopherol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14325</accession>
      <name>Masoprocol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14378</accession>
      <name>Aminosalicylic Acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14389</accession>
      <name>Mesalazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14614</accession>
      <name>Montelukast</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13974</accession>
      <name>4'-Hydroxydiclofenac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14849</accession>
      <name>Diethylcarbamazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13968</accession>
      <name>Hydroxyzileuton</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14933</accession>
      <name>Sulfasalazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15074</accession>
      <name>Meclofenamic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15149</accession>
      <name>Balsalazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15152</accession>
      <name>Minocycline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15229</accession>
      <name>Leflunomide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB30463</accession>
      <name>Hyperforin</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>lipoxygenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on single donors with incorporation of molecular oxygen</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>organic acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxoacid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>carboxylic acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>monocarboxylic acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>fatty acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>unsaturated fatty acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>icosanoid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>leukotriene metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>dendrite</description>
      <go_id>GO:0030425</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nuclear envelope lumen</description>
      <go_id>GO:0005641</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nuclear matrix</description>
      <go_id>GO:0016363</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nuclear membrane</description>
      <go_id>GO:0031965</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>sarcolemma</description>
      <go_id>GO:0042383</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>arachidonate 5-lipoxygenase activity</description>
      <go_id>GO:0004051</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>iron ion binding</description>
      <go_id>GO:0005506</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>lipoxygenase activity</description>
      <go_id>GO:0016165</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>acute inflammatory response</description>
      <go_id>GO:0002526</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>arachidonic acid metabolic process</description>
      <go_id>GO:0019369</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>leukotriene biosynthetic process</description>
      <go_id>GO:0019370</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>leukotriene production involved in inflammatory response</description>
      <go_id>GO:0002540</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>lipoxygenase pathway</description>
      <go_id>GO:0019372</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of vasoconstriction</description>
      <go_id>GO:0045907</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to hyperoxia</description>
      <go_id>GO:0055093</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to nutrient</description>
      <go_id>GO:0007584</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>sensory perception of pain</description>
      <go_id>GO:0019233</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasm</subcellular_location>
    <subcellular_location>Nucleus matrix</subcellular_location>
    <subcellular_location>Nucleus membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>10</chromosome_location>
    <locus>10q11.2</locus>
    <gene_sequence>&gt;2025 bp
ATGCCCTCCTACACGGTCACCGTGGCCACTGGCAGCCAGTGGTTCGCCGGCACTGACGAC
TACATCTACCTCAGCCTCGTGGGCTCGGCGGGCTGCAGCGAGAAGCACCTGCTGGACAAG
CCCTTCTACAACGACTTCGAGCGTGGCGCGGTGGATTCATACGACGTGACTGTGGACGAG
GAACTGGGCGAGATCCAGCTGGTCAGAATCGAGAAGCGCAAGTACTGGCTGAATGACGAC
TGGTACCTGAAGTACATCACGCTGAAGACGCCCCACGGGGACTACATCGAGTTCCCCTGC
TACCGCTGGATCACCGGCGATGTCGAGGTTGTCCTGAGGGATGGACGCGCAAAGTTGGCC
CGAGATGACCAAATTCACATTCTCAAGCAACACCGACGTAAAGAACTGGAAACACGGCAA
AAACAATATCGATGGATGGAGTGGAACCCTGGCTTCCCCTTGAGCATCGATGCCAAATGC
CACAAGGATTTACCCCGTGATATCCAGTTTGATAGTGAAAAAGGAGTGGACTTTGTTCTG
AATTACTCCAAAGCGATGGAGAACCTGTTCATCAACCGCTTCATGCACATGTTCCAGTCT
TCTTGGAATGACTTCGCCGACTTTGAGAAAATCTTTGTCAAGATCAGCAACACTATTTCT
GAGCGGGTCATGAATCACTGGCAGGAAGACCTGATGTTTGGCTACCAGTTCCTGAATGGC
TGCAACCCTGTGTTGATCCGGCGCTGCACAGAGCTGCCCGAGAAGCTCCCGGTGACCACG
GAGATGGTAGAGTGCAGCCTGGAGCGGCAGCTCAGCTTGGAGCAGGAGGTCCAGCAAGGG
AACATTTTCATCGTGGACTTTGAGCTGCTGGATGGCATCGATGCCAACAAAACAGACCCC
TGCACACTCCAGTTCCTGGCCGCTCCCATCTGCTTGCTGTATAAGAACCTGGCCAACAAG
ATTGTCCCCATTGCCATCCAGCTCAACCAAATCCCGGGAGATGAGAACCCTATTTTCCTC
CCTTCGGATGCAAAATACGACTGGCTTTTGGCCAAAATCTGGGTGCGTTCCAGTGACTTC
CACGTCCACCAGACCATCACCCACCTTCTGCGAACACATCTGGTGTCTGAGGTTTTTGGC
ATTGCAATGTACCGCCAGCTGCCTGCTGTGCACCCCATTTTCAAGCTGCTGGTGGCACAC
GTGAGATTCACCATTGCAATCAACACCAAGGCCCGTGAGCAGCTCATCTGCGAGTGTGGC
CTCTTTGACAAGGCCAACGCCACAGGGGGCGGTGGGCACGTGCAGATGGTGCAGAGGGCC
ATGAAGGACCTGACCTATGCCTCCCTGTGCTTTCCCGAGGCCATCAAGGCCCGGGGCATG
GAGAGCAAAGAAGACATCCCCTACTACTTCTACCGGGACGACGGGCTCCTGGTGTGGGAA
GCCATCAGGACGTTCACGGCCGAGGTGGTAGACATCTACTACGAGGGCGACCAGGTGGTG
GAGGAGGACCCGGAGCTGCAGGACTTCGTGAACGATGTCTACGTGTACGGCATGCGGGGC
CGCAAGTCCTCAGGCTTCCCCAAGTCGGTCAAGAGCCGGGAGCAGCTGTCGGAGTACCTG
ACCGTGGTGATCTTCACCGCCTCCGCCCAGCACGCCGCGGTCAACTTCGGCCAGTACGAC
TGGTGCTCCTGGATCCCCAATGCGCCCCCAACCATGCGAGCCCCGCCACCGACTGCCAAG
GGCGTGGTGACCATTGAGCAGATCGTGGACACGCTGCCCGACCGCGGCCGCTCCTGCTGG
CATCTGGGTGCAGTGTGGGCGCTGAGCCAGTTCCAGGAAAACGAGCTGTTCCTGGGCATG
TACCCAGAAGAGCATTTTATCGAGAAGCCTGTGAAGGAAGCCATGGCCCGATTCCGCAAG
AACCTCGAGGCCATTGTCAGCGTGATTGCTGAGCGCAACAAGAAGAAGCAGCTGCCATAT
TACTACTTGTCCCCAGACCGGATTCCGAACAGTGTGGCCATCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>674</residue_number>
    <molecular_weight>77982.595</molecular_weight>
    <theoretical_pi>5.775</theoretical_pi>
    <pfams>
      <pfam>
        <name>Lipoxygenase</name>
        <pfam_id>PF00305</pfam_id>
      </pfam>
      <pfam>
        <name>PLAT</name>
        <pfam_id>PF01477</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Arachidonate 5-lipoxygenase
MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDE
ELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLA
RDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVL
NYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNG
CNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDP
CTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDF
HVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECG
LFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWE
AIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYL
TVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCW
HLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPY
YYLSPDRIPNSVAI</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P09917</uniprot_id>
  <uniprot_name>LOX5_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>2ABV</pdb_id>
    <pdb_id>3O8Y</pdb_id>
    <pdb_id>3V92</pdb_id>
    <pdb_id>3V98</pdb_id>
    <pdb_id>3V99</pdb_id>
  </pdb_ids>
  <genbank_gene_id>J03600</genbank_gene_id>
  <genecard_id>ALOX5</genecard_id>
  <geneatlas_id>ALOX5</geneatlas_id>
  <hgnc_id>HGNC:435</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Dixon RA, Jones RE, Diehl RE, Bennett CD, Kargman S, Rouzer CA: Cloning of the cDNA for human 5-lipoxygenase.  Proc Natl Acad Sci U S A. 1988 Jan;85(2):416-20.</reference_text>
      <pubmed_id>3422434</pubmed_id>
    </reference>
    <reference>
      <reference_text>Matsumoto T, Funk CD, Radmark O, Hoog JO, Jornvall H, Samuelsson B: Molecular cloning and amino acid sequence of human 5-lipoxygenase.  Proc Natl Acad Sci U S A. 1988 Jan;85(1):26-30.</reference_text>
      <pubmed_id>2829172</pubmed_id>
    </reference>
    <reference>
      <reference_text>Matsumoto T, Funk CD, Radmark O, Hoog JO, Jornvall H, Samuelsson B: Molecular cloning and amino acid sequence of human 5-lipoxygenase.  Adv Prostaglandin Thromboxane Leukot Res. 1989;19:466-9.</reference_text>
      <pubmed_id>2526519</pubmed_id>
    </reference>
    <reference>
      <reference_text>Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J: The DNA sequence and comparative analysis of human chromosome 10.  Nature. 2004 May 27;429(6990):375-81.</reference_text>
      <pubmed_id>15164054</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Funk CD, Hoshiko S, Matsumoto T, Rdmark O, Samuelsson B: Characterization of the human 5-lipoxygenase gene.  Proc Natl Acad Sci U S A. 1989 Apr;86(8):2587-91.</reference_text>
      <pubmed_id>2565035</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hoshiko S, Radmark O, Samuelsson B: Characterization of the human 5-lipoxygenase gene promoter.  Proc Natl Acad Sci U S A. 1990 Dec;87(23):9073-7.</reference_text>
      <pubmed_id>2251250</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rouzer CA, Samuelsson B: Reversible, calcium-dependent membrane association of human leukocyte 5-lipoxygenase. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7393-7.</reference_text>
      <pubmed_id>3118366</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nguyen T, Falgueyret JP, Abramovitz M, Riendeau D: Evaluation of the role of conserved His and Met residues among lipoxygenases by site-directed mutagenesis of recombinant human 5-lipoxygenase. J Biol Chem. 1991 Nov 15;266(32):22057-62.</reference_text>
      <pubmed_id>1939225</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ishii S, Noguchi M, Miyano M, Matsumoto T, Noma M: Mutagenesis studies on the amino acid residues involved in the iron-binding and the activity of human 5-lipoxygenase. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1482-90.</reference_text>
      <pubmed_id>1540191</pubmed_id>
    </reference>
    <reference>
      <reference_text>Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, Heibein JA, Charleson S, Singer II: 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med. 1993 Dec 1;178(6):1935-46.</reference_text>
      <pubmed_id>8245774</pubmed_id>
    </reference>
    <reference>
      <reference_text>Werz O, Szellas D, Steinhilber D, Radmark O: Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem. 2002 Apr 26;277(17):14793-800. Epub 2002 Feb 13.</reference_text>
      <pubmed_id>11844797</pubmed_id>
    </reference>
    <reference>
      <reference_text>Luo M, Jones SM, Phare SM, Coffey MJ, Peters-Golden M, Brock TG: Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem. 2004 Oct 1;279(40):41512-20. Epub 2004 Jul 26.</reference_text>
      <pubmed_id>15280375</pubmed_id>
    </reference>
    <reference>
      <reference_text>Flamand N, Lefebvre J, Surette ME, Picard S, Borgeat P: Arachidonic acid regulates the translocation of 5-lipoxygenase to the nuclear membranes in human neutrophils. J Biol Chem. 2006 Jan 6;281(1):129-36. Epub 2005 Nov 7.</reference_text>
      <pubmed_id>16275640</pubmed_id>
    </reference>
    <reference>
      <reference_text>Strid T, Svartz J, Franck N, Hallin E, Ingelsson B, Soderstrom M, Hammarstrom S: Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein. Biochem Biophys Res Commun. 2009 Apr 17;381(4):518-22. Epub 2009 Feb 20.</reference_text>
      <pubmed_id>19233132</pubmed_id>
    </reference>
    <reference>
      <reference_text>Flamand N, Luo M, Peters-Golden M, Brock TG: Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export. J Biol Chem. 2009 Jan 2;284(1):306-13. Epub 2008 Nov 1.</reference_text>
      <pubmed_id>18978352</pubmed_id>
    </reference>
    <reference>
      <reference_text>Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC: Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 2004 Dec;25(12):2467-72. Epub 2004 Aug 12.</reference_text>
      <pubmed_id>15308583</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-Tocopherol</name>
        <accession>HMDB01893</accession>
      </metabolite>
      <reference>
        <reference_text>Taccone-Gallucci M, Manca-di-Villahermosa S, Battistini L, Stuffler RG, Tedesco M, Maccarrone M: N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. Kidney Int. 2006 Apr;69(8):1450-4.</reference_text>
        <pubmed_id>16531984</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Masoprocol</name>
        <accession>HMDB14325</accession>
      </metabolite>
      <reference>
        <reference_text>Audouin C, Mestdagh N, Lassoie MA, Houssin R, Henichart JP: N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase.  Bioorg Med Chem Lett. 2001 Mar 26;11(6):845-8.</reference_text>
        <pubmed_id>11277534</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Masoprocol</name>
        <accession>HMDB14325</accession>
      </metabolite>
      <reference>
        <reference_text>Lambert JD, Meyers RO, Timmermann BN, Dorr RT: Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):85-90.</reference_text>
        <pubmed_id>11318430</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Masoprocol</name>
        <accession>HMDB14325</accession>
      </metabolite>
      <reference>
        <reference_text>Azadzoi KM, Heim VK, Tarcan T, Siroky MB: Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanoids. Neurourol Urodyn. 2004;23(3):258-64.</reference_text>
        <pubmed_id>15098224</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Masoprocol</name>
        <accession>HMDB14325</accession>
      </metabolite>
      <reference>
        <reference_text>West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, Gabbita SP, Hamdheydari L, Mai T, Mou S, Pye QN, Stewart C, West S, Williamson KS, Zemlan F, Hensley K: The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem. 2004 Oct;91(1):133-43.</reference_text>
        <pubmed_id>15379894</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Masoprocol</name>
        <accession>HMDB14325</accession>
      </metabolite>
      <reference>
        <reference_text>Jeon SB, Ji KA, You HJ, Kim JH, Jou I, Joe EH: Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes. Biochem Biophys Res Commun. 2005 Mar 11;328(2):595-600.</reference_text>
        <pubmed_id>15694390</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Masoprocol</name>
        <accession>HMDB14325</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminosalicylic Acid</name>
        <accession>HMDB14378</accession>
      </metabolite>
      <reference>
        <reference_text>Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82.</reference_text>
        <pubmed_id>2882965</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminosalicylic Acid</name>
        <accession>HMDB14378</accession>
      </metabolite>
      <reference>
        <reference_text>Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51.</reference_text>
        <pubmed_id>6428914</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminosalicylic Acid</name>
        <accession>HMDB14378</accession>
      </metabolite>
      <reference>
        <reference_text>Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2.</reference_text>
        <pubmed_id>6131674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82.</reference_text>
        <pubmed_id>2882965</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51.</reference_text>
        <pubmed_id>6428914</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2.</reference_text>
        <pubmed_id>6131674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Montelukast</name>
        <accession>HMDB14614</accession>
      </metabolite>
      <reference>
        <reference_text>Ramires R, Caiaffa MF, Tursi A, Haeggstrom JZ, Macchia L: Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun. 2004 Nov 12;324(2):815-21.</reference_text>
        <pubmed_id>15474500</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Charlier C, Michaux C: Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem. 2003 Jul-Aug;38(7-8):645-59.</reference_text>
        <pubmed_id>12932896</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Kudo C, Kori M, Matsuzaki K, Yamai K, Nakajima A, Shibuya A, Niwa H, Kamisaki Y, Wada K: Diclofenac inhibits proliferation and differentiation of neural stem cells.  Biochem Pharmacol. 2003 Jul 15;66(2):289-95.</reference_text>
        <pubmed_id>12826271</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Whittle BJ: Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs. Curr Opin Pharmacol. 2004 Dec;4(6):538-45.</reference_text>
        <pubmed_id>15525540</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylcarbamazine</name>
        <accession>HMDB14849</accession>
      </metabolite>
      <reference>
        <reference_text>Bach MK, Brashler JR: Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor. Biochem Pharmacol. 1986 Feb 1;35(3):425-33.</reference_text>
        <pubmed_id>3004501</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylcarbamazine</name>
        <accession>HMDB14849</accession>
      </metabolite>
      <reference>
        <reference_text>Cernak I, Savic J, Malicevic Z, Zunic G, Radosevic P, Ivanovic I: Leukotrienes in the pathogenesis of pulmonary blast injury.  J Trauma. 1996 Mar;40(3 Suppl):S148-51.</reference_text>
        <pubmed_id>8606397</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylcarbamazine</name>
        <accession>HMDB14849</accession>
      </metabolite>
      <reference>
        <reference_text>Gross NJ, Holloway NO, Narine KR: Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis. Radiat Res. 1991 Sep;127(3):317-24.</reference_text>
        <pubmed_id>1886988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylcarbamazine</name>
        <accession>HMDB14849</accession>
      </metabolite>
      <reference>
        <reference_text>Zunic G, Cernak I, Malicevic Z, Savic J: Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.</reference_text>
        <pubmed_id>10518442</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylcarbamazine</name>
        <accession>HMDB14849</accession>
      </metabolite>
      <reference>
        <reference_text>Davidson D, Drafta D: Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4 in the rat lung. J Appl Physiol. 1992 Sep;73(3):955-61.</reference_text>
        <pubmed_id>1400062</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylcarbamazine</name>
        <accession>HMDB14849</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Wenzel SE: Leukotriene receptor antagonists and related compounds.  Can Respir J. 1999 Mar-Apr;6(2):189-93.</reference_text>
        <pubmed_id>10322101</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Hardy DB, Pereria LE, Yang K: Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. Biol Reprod. 1999 Jul;61(1):40-5.</reference_text>
        <pubmed_id>10377029</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Yamashita M, Kushihara M, Hirasawa N, Takasaki W, Takahagi H, Takayanagi M, Ohuchi K: Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells. Br J Pharmacol. 2000 Jan;129(2):367-73.</reference_text>
        <pubmed_id>10694244</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Qian C, Hwang SB, Libertine-Garahan L, Eckman JB, Cai X, Scannell RT, Yeh CG: Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.</reference_text>
        <pubmed_id>11529688</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Coffey MJ, Phare SM, Peters-Golden M: Peroxynitrite-induced nitrotyrosination of proteins is blocked by direct 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther. 2001 Oct;299(1):198-203.</reference_text>
        <pubmed_id>11561080</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Zouboulis CC: Zileuton, a new efficient and safe systemic anti-acne drug.  Dermatoendocrinol. 2009 May;1(3):188-92.</reference_text>
        <pubmed_id>20436887</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Zouboulis CC, Seltmann H, Alestas T: Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol. 2010 Feb;19(2):148-50. Epub 2009 Jul 23.</reference_text>
        <pubmed_id>19645854</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Berger W, De Chandt MT, Cairns CB: Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract. 2007 Apr;61(4):663-76.</reference_text>
        <pubmed_id>17394438</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Guidot DM, Repine MJ, Westcott JY, Repine JE: Intrinsic 5-lipoxygenase activity is required for neutrophil responsivity.  Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8156-9.</reference_text>
        <pubmed_id>8058773</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Wenzel SE, Kamada AK: Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.  Ann Pharmacother. 1996 Jul-Aug;30(7-8):858-64.</reference_text>
        <pubmed_id>8826571</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82.</reference_text>
        <pubmed_id>2882965</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51.</reference_text>
        <pubmed_id>6428914</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2.</reference_text>
        <pubmed_id>6131674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclofenamic acid</name>
        <accession>HMDB15074</accession>
      </metabolite>
      <reference>
        <reference_text>Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells. Am J Physiol. 1992 Feb;262(2 Pt 1):L229-34.</reference_text>
        <pubmed_id>1539679</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclofenamic acid</name>
        <accession>HMDB15074</accession>
      </metabolite>
      <reference>
        <reference_text>Boctor AM, Eickholt M, Pugsley TA: Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38.</reference_text>
        <pubmed_id>3020588</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84.</reference_text>
        <pubmed_id>19743890</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K: 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.  Agents Actions. 1992;Spec No:C37-46.</reference_text>
        <pubmed_id>1359745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Minocycline</name>
        <accession>HMDB15152</accession>
      </metabolite>
      <reference>
        <reference_text>Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4.</reference_text>
        <pubmed_id>15371729</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Minocycline</name>
        <accession>HMDB15152</accession>
      </metabolite>
      <reference>
        <reference_text>Song Y, Wei EQ, Zhang WP, Ge QF, Liu JR, Wang ML, Huang XJ, Hu X, Chen Z: Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res. 2006 Apr 26;1085(1):57-67. Epub 2006 Mar 30.</reference_text>
        <pubmed_id>16574083</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Minocycline</name>
        <accession>HMDB15152</accession>
      </metabolite>
      <reference>
        <reference_text>Chu LS, Fang SH, Zhou Y, Yu GL, Wang ML, Zhang WP, Wei EQ: Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin. 2007 Jun;28(6):763-72.</reference_text>
        <pubmed_id>17506934</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hyperforin</name>
        <accession>HMDB30463</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
